Carmignac Gestion Clearside Biomedical, Inc. Transaction History
Carmignac Gestion
- $5.85 Billion
- Q1 2025
A detailed history of Carmignac Gestion transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Carmignac Gestion holds 1,508,342 shares of CLSD stock, worth $633,503. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,508,342
Previous 1,933,531
21.99%
Holding current value
$633,503
Previous $1.93 Million
28.25%
% of portfolio
0.02%
Previous 0.03%
Shares
12 transactions
Others Institutions Holding CLSD
# of Institutions
51Shares Held
11.4MCall Options Held
5.9KPut Options Held
86.6K-
Vanguard Group Inc Valley Forge, PA2.81MShares$1.18 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$922,9413.43% of portfolio
-
Black Rock Inc. New York, NY798KShares$335,2170.0% of portfolio
-
Geode Capital Management, LLC Boston, MA792KShares$332,7430.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny555KShares$232,8950.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $25.3M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...